Bristol/AstraZeneca Demonstrate Safety In Dapagliflozin Study For Type 2 Diabetes
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies report Phase IIa data evaluating the sodium-glucose transporter 2 inhibitor at American Diabetes Association meeting.